Cantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $7 price target.
March 28, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating and a $7 price target on Mereo BioPharma Group.
The reiteration of an Overweight rating and maintenance of a $7 price target by a reputable analyst firm like Cantor Fitzgerald suggests a positive outlook for Mereo BioPharma Group. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100